Skip to search formSkip to main contentSkip to account menu

Anti-Drug Antibody

Known as: ADA, Anti-Drug Antibodies 
An antibody that binds to an administered drug. Expression of these antibodies is thought to be induced by (repeated) drug administration.
National Institutes of Health

Related topics

Related topics

2 relations
Immune System Processesantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OP0021 Efficacy and safety results of a phase iii study comparing fkb327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis
Background FKB327 is a proposed biosimilar of the adalimumab reference product (ADL). This randomised, double-blind, Phase III… 
2016
2016
An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
2016
2016
Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration
In their 2015 publication, Emery et al 1 reported findings of a phase III, randomised, double-blind study comparing the… 
2015
2015
Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.
3058 Background: The anti–PD-1 antibody pembro has efficacy in advanced cancer pts. We characterized pembro PK properties and… 
Review
2014
Review
2014
TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
Since their appearance in the armamentarium for inflammatory bowel disease (IBD) more than a decade ago, antitumor necrosis… 
2014
2014
Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis.
Review
2012
Review
2012
Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics.
2012
2012
IMMUNOGENICITY OF TRASTUZUMAB INTRAVENOUS AND SUBCUTANEOUS FORMULATIONS IN THE PHASE III HANNAH STUDY
2011
2011
High cancer risk and increased mortality in patients with Peutz–Jeghers syndrome
We read with interest the informative, and needed, update on the Dutch Peutz–Jeghers syndrome (PJS) cohort by van Lier et al .1… 
Review
2009
Review
2009
Strategies for preclinical immunogenicity assessment of protein therapeutics.
The immunogenicity assessment of protein therapeutics has received significant attention, both from regulatory bodies and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)